These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

580 related items for PubMed ID: 7667342

  • 1. Involvement of N-methyl-D-aspartate (NMDA) receptors in noncompetitive NMDA receptor antagonist-induced hyperlocomotion in mice.
    Irifune M, Shimizu T, Nomoto M, Fukuda T.
    Pharmacol Biochem Behav; 1995; 51(2-3):291-6. PubMed ID: 7667342
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of D1 and D2 dopamine receptor antagonists and catecholamine depleting agents on the locomotor stimulation induced by dizocilpine in mice.
    Lapin IP, Rogawski MA.
    Behav Brain Res; 1995 Oct; 70(2):145-51. PubMed ID: 8561905
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. NMDA receptor antagonists inhibit apomorphine-induced climbing behavior not only in intact mice but also in reserpine-treated mice.
    Kim HS, Rhee GS, Oh S, Park WK.
    Behav Brain Res; 1999 Apr; 100(1-2):135-42. PubMed ID: 10212060
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phencyclidine- and dizocilpine-induced hyperlocomotion are differentially mediated.
    Ogren SO, Goldstein M.
    Neuropsychopharmacology; 1994 Nov; 11(3):167-77. PubMed ID: 7865098
    [Abstract] [Full Text] [Related]

  • 12. NMDA receptor inhibition prevents tolerance to cocaine.
    De Montis MG, Devoto P, Meloni D, Gambarana C, Giorgi G, Tagliamonte A.
    Pharmacol Biochem Behav; 1992 May; 42(1):179-82. PubMed ID: 1356273
    [Abstract] [Full Text] [Related]

  • 13. Chronic treatment with caffeine blunts the hyperlocomotor but not cognitive effects of the N-methyl-D-aspartate receptor antagonist MK-801 in mice.
    Dall'Igna OP, Da Silva AL, Dietrich MO, Hoffmann A, de Oliveira RV, Souza DO, Lara DR.
    Psychopharmacology (Berl); 2003 Mar; 166(3):258-63. PubMed ID: 12589526
    [Abstract] [Full Text] [Related]

  • 14. Prenatal exposure to an NMDA receptor antagonist, MK-801 reduces density of parvalbumin-immunoreactive GABAergic neurons in the medial prefrontal cortex and enhances phencyclidine-induced hyperlocomotion but not behavioral sensitization to methamphetamine in postpubertal rats.
    Abekawa T, Ito K, Nakagawa S, Koyama T.
    Psychopharmacology (Berl); 2007 Jun; 192(3):303-16. PubMed ID: 17340116
    [Abstract] [Full Text] [Related]

  • 15. The novel competitive N-methyl-D-aspartate (NMDA) antagonist CGP 37849 preferentially induces phencyclidine-like behavioral effects in kindled rats: attenuation by manipulation of dopamine, alpha-1 and serotonin1A receptors.
    Löscher W, Hönack D.
    J Pharmacol Exp Ther; 1991 Jun; 257(3):1146-53. PubMed ID: 1675288
    [Abstract] [Full Text] [Related]

  • 16. Many agents that antagonize the NMDA receptor-channel complex in vivo also cause disturbances of motor coordination.
    Carter AJ.
    J Pharmacol Exp Ther; 1994 May; 269(2):573-80. PubMed ID: 7514220
    [Abstract] [Full Text] [Related]

  • 17. Rodent data and general hypothesis: antipsychotic action exerted through 5-Ht2A receptor antagonism is dependent on increased serotonergic tone.
    Martin P, Waters N, Schmidt CJ, Carlsson A, Carlsson ML.
    J Neural Transm (Vienna); 1998 May; 105(4-5):365-96. PubMed ID: 9720968
    [Abstract] [Full Text] [Related]

  • 18. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade.
    Leriche L, Schwartz JC, Sokoloff P.
    Neuropharmacology; 2003 Aug; 45(2):174-81. PubMed ID: 12842123
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.